Revenue (Tables)

9 Months Ended

Sep. 30, 2020

Risks and Uncertainties [Abstract]

Disaggregation of Revenue

The following table and description below shows the products from which the Company generated its revenue:

	Three Months Ended September 30,				Nine Months Ended September 30,
Revenue by product (in thousands)	2020		2019		2020		2019
MACI implants and kits
Implants based on contracted rate sold through a specialty pharmacy (a)	$	14,897	$	11,779	$	36,084	$	34,555
Implants subject to third party reimbursement sold through a specialty pharmacy (b)	3,529		4,030		10,299		10,584
Implants sold direct based on contracted rates (c)	4,602		3,039		9,528		9,715
Implants sold direct subject to third party reimbursement (d)	782		573		1,793		1,176
Biopsy kits - direct bill	539		533		1,348		1,632
Change in estimates related to prior periods (e)	8		656		695		353
Epicel
Direct bill (hospital)	6,663		9,889		17,965		20,445
Total product revenue	$	31,020	$	30,499	$	77,712	$	78,460
Other revenue (f)	1,238		—		1,238		—
Total net revenue	$	32,258	$	30,499	$	78,950	$	78,460
(a) Represents implants sold through Orsini and AllCare in both 2020 and 2019 whereby such specialty pharmacies have a direct contract with the underlying insurance provider. The amount of reimbursement is based on contracted rates at the time of sale supported by the pharmacy's direct contracts.
(b) Represents implants sold through Orsini or AllCare whereby such specialty pharmacy does not have a direct contract with the underlying payer. The amount of reimbursement is established based on a payer or state fee schedule and/or payer history.
(c) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. Also represents direct sales under a contract to the specialty distributor DMS.
(d) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. The payment terms are subject to third-party reimbursement from an underlying insurance provider.
(e) Primarily represents changes in estimates related to implants sold through Orsini or AllCare in which such specialty pharmacy does not have a direct contract with the underlying payer. The initial estimate of the amount of reimbursement is established based on a payer or state fee schedule and/or payer history. The change in estimates is a result of additional information or actual cash collections received in the current period.
(f) Represents income from sales of NexoBrid to BARDA, pursuant to the license agreement between the Company and MediWound.